KYNTRA BIO, INC.

BUSI NESS OVERVIEW Kyntra Bio, Inc. ( Kyntra Bio or the Company ) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. In January 2026, the Company announced its rebranding from FibroGen, Inc. to Kyntra Bio, Inc. , representing the next step of its transformation and focus on oncology and associated rare disease indications. On January 8, 2026, the Company’s common stock began trading under the new Nasdaq symbol KYNB. We are developing FG-3246, a potential first-in-class antibody-drug conjugate ( ADC ) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer ( mCRPC ) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography ( PET ) biomarker and imaging agent. We initiated a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory sub-study of FG-3180, in the third quarter of 2025. We and our collaboration partners developed roxadustat ( , EVRENZO TM ), which is currently approved in Europe, Japan, the People’s Republic of China ( China ), and numerous other countries for the treatment of anemia in chronic kidney disease ( CKD ) patients on dialysis and not on dialysis. On August 29, 2025, we closed the sale of our China operations through FibroGen International (Hong Kong) Ltd.